Company Overview of Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC engages in the design, development, and commercialization of kinase-inhibiting drugs for the treatment of cancers and immunological diseases. The company develops therapeutic agents against leukemia, invasive cancers, melanoma, gastrointestinal stromal tumors, bone metastases, and autoimmune diseases. Its drug pipeline comprises DCC-2036 for chronic myeloid leukemia, acute lymphocytic leukemia, and acute myeloid leukemia; DCC-2618 for gastrointestinal stromal tumors, mast cell leukemia, and mastocytosis; DCC-2701 and DCC-2721 for solid tumors and metastatic cancers; DCC-2909 for cancer invasiveness and bone metastasis; and cFMS kinase program for autoimmune dis...
Lawrence, KS 66044
Founded in 2003
Key Executives for Deciphera Pharmaceuticals, LLC
Chief Executive Officer, President and Member of the Board of Managers
Founder, Chief Scientific Officer and Member of the Board of Managers
Head of Regulatory Affairs & Clinical Operations
Compensation as of Fiscal Year 2015.
Deciphera Pharmaceuticals, LLC Key Developments
Deciphera Eyes Listing In 12-18 Months
Sep 21 15
Deciphera Pharmaceuticals, LLC may get listed in near future, reported Boston Business Journal on September 21, 2015. Mike Taylor, Chief Executive Officer of Deciphera Pharmaceuticals said, "We just want to go out from a position of strength," he added that "By the end of 2016 we’d be looking at transitioning toward a public company."
Deciphera Pharmaceuticals Announces the Publication of Study Results of its Phase 1 Anti-Cancer Product Candidate, Altiratinib, Abalanced, Spectrum-Selective Inhibitor of MET, TIE2, and VEGFR2 kinases
Aug 18 15
Deciphera Pharmaceuticals announced the publication of study results describing the preclinical profile of its Phase 1 anti-cancer product candidate, altiratinib, abalanced, spectrum-selective inhibitor of MET, TIE2, and VEGFR2 kinases. Altiratinib is currently in Phase 1 clinical evaluation in cancer patients (NCT02228811). In the article the authors describe how altiratinib’s balanced inhibition of the three key kinases, MET, TIE2, and VEGFR2 was achieved using Deciphera’s proprietary switch control kinase inhibitor platform. Moreover, altiratinib was shown to inhibit not only wild type MET, but also oncogenic mutant forms of MET not readily inhibited by other MET inhibitors in development. The ability to inhibit MET mutants during the course of treatment is a key component to altiratinib’s product profile, which Deciphera believes will provide more durable therapy for cancer patients compared to existing agents. MET mutations are driver mutations in certain cancers and can also arise as a resistance mechanism in patients with pre-existing MET amplifications, highlighting the need for durable inhibition of various forms of genomically altered MET. The report further discloses altiratinib’s ability to block drug resistance mechanisms mediated by the tumor microenvironment. Through its balanced inhibitory potency, altiratinib was shown to inhibit three major evasive cancer (re)vascularization and resistance pathways with comparable single-digit nanomolar inhibitory potency, including HGF, ANG, and VEGF and to block tumor invasion and metastasis. Notably, in a glioblastoma tumor model known to exhibit these tumor microenvironment disease progression mechanisms, altiratinib was shown to double the overall survival of mice compared to vehicle control treated mice and, in combination with bevacizumab, to double survival compared to single-agent bevacizumab-treated mice.
Deciphera Pharmaceuticals Scientific Appoints Members to its Scientific Advisory Board
Jun 23 15
Deciphera Pharmaceuticals announced that three new members have joined its Scientific Advisory Board, which serves as a strategic resource to Deciphera as it develops its switch-pocket inhibitors for the treatment of cancers. The new members of the Scientific Advisory Board are: Jean-Yves Blay, MD, General Director of the Centre Léon Bérard, in Lyon, France. Stephen Hodi, MD, Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Assistant Professor of Medicine at Harvard Medical School; and Filip Janku, MD, PhD, Assistant Professor in the Department of Investigational Cancer Therapeutics (phase 1 program) at MD Anderson Cancer Center. Jean-Yves Blay, MD is a medical oncologist, researcher, and professor. He currently holds the position of General Director of the Centre Léon Bérard, in Lyon, France, and additionally maintains active roles at this institution including Professor of Medical Oncology at the Université Claude Bernard Lyon 1, Head of the Integrated Research Site of Lyon (LYric) of the French National Cancer Institute, Director of the Network of Reference Centers for Sarcomas in France, Chairman of the French Sarcoma Group, and Director of the Institute for Clinical Science. F. Stephen Hodi, MD is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Assistant Professor of Medicine at Harvard Medical School. Filip Janku, MD, PhD is an Assistant Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) at MD Anderson Cancer Center.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 14, 2015